UNICHEMLAB.NSE · Unichem Laboratories Limited

-

Please sign in to comment on UNICHEMLAB.NSE

1 Comment

Admin

4 years ago

Unichem Laboratories Limited is currently in a long term uptrend where the price is trading 10.9% above its 200 day moving average.

From a valuation standpoint, the stock is 64.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.

Unichem Laboratories Limited's total revenue rose by 9.8% to $3B since the same quarter in the previous year.

Its net income has increased by 261.4% to $236M since the same quarter in the previous year.

Finally, its free cash flow fell by 21.9% to $-353M since the same quarter in the previous year.

Based on the above factors, Unichem Laboratories Limited gets an overall score of 4/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	NSE
CurrencyCode	INR
ISIN	INE351A01035

Market Cap	45B
PE Ratio	None
Target Price	None
Beta	0.22
Dividend Yield	None

ABOUT

Unichem Laboratories Limited

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. Unichem Laboratories Limited was founded in 1944 and is based in Mumbai, India.

UNICHEMLAB.NSE · Unichem Laboratories Limited

-

Unichem Laboratories Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Unichem Laboratories Limited using a moving average strategy